CLEIDE GUIMARAES MACHADO CARANI

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: Macular edema ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • article 11 Citação(ões) na Scopus
    Effect of a Single Intravitreal Bevacizumab Injection on Contrast Sensitivity and Macular Thickness in Eyes with Macular Edema from Central Retinal Vein Occlusion: A Prospective, Nonrandomized, Three-Month Follow-Up Study
    (2014) PRETI, Rony C.; RAMIREZ, Lisa M. V.; PIMENTEL, Sergio L. G.; NAKASHIMA, Yoshitaka; MACHADO, Cleide G.; PELAYES, David E.; MONTEIRO, Mario L. R.; TAKAHASHI, Walter Y.
    Purpose: To evaluate the results of intravitreal bevacizumab (IVB) injection on contrast sensitivity (CS), best-corrected visual acuity (BCVA), foveal thickness (FT) and macular volume (MV) as measured by optical coherence tomography in patients with macular edema (ME) from central retinal vein occlusion (CRVO). Methods: Sixteen consecutive eyes from 16 patients with ME from unilateral CRVO were treated with a single IVB injection. The CS, BCVA, FT and MV measurements were obtained before the treatment and 1 and 3 months after the injection. Results: CS demonstrated significant improvement at all spatial frequencies - 1.5, 3, 6, 12 and 18 cycles per degree (cpd) - 1 month after the injection and at 6 cpd at the 3-month follow-up. The mean BCVA measurements in log of the minimum angle of resolution (logMAR) units improved from 1.03 at baseline to 0.83 logMAR 1 month after the injection, but worsened to 0.97 logMAR at 3 months. The mean baseline FT +/- standard deviation (SD; 620.06 +/- 177.60 mu m) was reduced significantly 1 month (270.93 +/- 74.17 mu m) and 3 months (535.56 +/- 222.33 mu m) after the treatment. The mean baseline MV +/- SD (12,765.56 +/- 3,769.70 mm 3) was reduced significantly at the 1-month (8,324.93 +/- 932.04 mm(3)) and 3-month (11,319.44 +/- 3,044.74 mm(3)) follow-up visits. Conclusions: IVB improved CS, BCVA, FT and MV within a short time period (1 month). Although VA was not improved at 3 months, improvements were observed for CS, FT and MV, which indicates that, despite ME recurrence, there still was some benefit to visual function. (C) 2014 S. Karger AG, Basel
  • article 6 Citação(ões) na Scopus
    Profilaxia e tratamento do edema macular cistoide após cirurgia de catarata
    (2015) CARRICONDO, Pedro C.; ABALEM, Maria Fernanda; MACHADO, Cleide Guimarães; KARA-JUNIOR, Newton
    Macular cystoid edema is one of the major causes of decreased vision after cataract surgery. The inflammatory process appears to be the main causal factor of the edema. The major risk factors are: surgical complications, previous retinal diseases, diabetes, uveitis and use of prostaglandins drops. The diagnosis is clinically, but fluorescein angiography and optical coherence tomography are also important to detect swelling and assist in differential diagnosis. Although pre-operative prophylaxis do not have scientific evidence, it is recommended especially in cases with risk factors. The initial treatment includes a combination of both topic corticosteroid and nonsteroidal anti-inflammatory. Chronic and refractory cases can be managed with alternatives treatment, such as intravitreal triamcinolone and anti-angiogenic. This article aims to discuss various aspects of pseudophakic macular cystoid edema.
  • article 11 Citação(ões) na Scopus
    Single intravitreal bevacizumab injection effects on contrast sensitivity in macular edema from branch retinal vein occlusion
    (2012) PRETI, Rony Carlos; RAMIREZ, Lisa Mariel Vasquez; PIMENTEL, Sergio Luis Gianotti; MOTTA, Augusto Alves Lopes; MACHADO, Cleide Guimaraes; MONTEIRO, Mario Luiz Ribeiro; TAKAHASHI, Walter Yukihiko
    Purpose: To evaluate the effect of a single intravitreal bevacizumab injection on visual acuity, contrast sensitivity and optical coherence tomography-measured central macular thickness in eyes with macular edema from branch retinal vein occlusion. Methods: Seventeen eyes of 17 patients with macular edema from unilateral branch retinal vein occlusion were treated with a single bevacizumab injection. Patients were submitted to a complete evaluation including best corrected visual acuity, contrast sensitivity and optical coherence tomography measurements before treatment and one and three months after injection. Visual acuity, contrast sensitivity and optical coherence tomography measurements were compared to baseline values. Results: Mean visual acuity measurement improved from 0.77 logMAR at baseline to 0.613 logMAR one month after injection (P=0.0001) but worsened to 0.75 logMAR after three months. Contrast sensitivity test demonstrated significant improvement at spatial frequencies of 3, 6, 12 and 18 cycles/degree one month after injection and at the spatial frequency of 12 cycles/degree three months after treatment. Mean +/- standard deviation baseline central macular thickness (552 +/- 150 mu m) reduced significantly one month (322 +/- 127 mu m, P=0.0001) and three months (439 perpendicular to 179 mu m, P=0.01) after treatment. Conclusions: Bevacizumab injection improves visual acuity and contrast sensitivity and reduces central macular thickness one month after treatment. Visual acuity returns to baseline levels at the 3-month follow-up, but some beneficial effect of the treatment is still present at that time, as evidenced by optical coherence tomography-measured central macular thickness and contrast sensitivity measurements.